Liposome Co. anticancer agents
Executive Summary
IND reviews for liposomal formulations of doxorubicin (TLC-DOX99) and a platinum derivative (TLC-PLAT23) have been completed by FDA and human testing in the U.S. will begin "shortly" at Roswell Park Memorial Institute and M.D. Anderson Hospital and Tumor Institute. Princeton, N.J.-based Liposome Company announced the status of trials in a Feb. 29 press release.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.